articleThe LancetNov 1, 2003Closed access

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

SBS. Bertil Olsson?

Lund University

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

810
total citations
FWCI
66.87
Percentile
100%
References
35
Citations per year

Authors

2

Topics & keywords

Topics
Keywords
  • Ximelagatran
  • Medicine
  • Warfarin
  • Atrial fibrillation
  • Stroke (engine)
  • Direct thrombin inhibitor
  • Clinical endpoint
  • Embolism
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.